• Explore /
  • Poster
  • / Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

Abstract Video & Slides Poster

Authors

null

Catherine S. Magid Diefenbach

Perlmutter Cancer Center at NYU Langone Health, New York, NY

Catherine S. Magid Diefenbach , Pau Abrisqueta , Eva Gonzalez-Barca , Carlos Panizo , Jose Maria Arguinano Perez , Fiona Miall , Mariana Bastos-Oreiro , Armando Lopez-Guillermo , Lalita Banerjee , Andrew McMillan , Jamie Hirata , Lisa Musick , Sourish Saha , Brandon Croft , Erlene Kuizon Seymour

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02600897

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7512)

DOI

10.1200/JCO.2021.39.15_suppl.7512

Abstract #

7512

Abstract Disclosures

Similar Posters

First Author: Bei Hu

First Author: Jason Westin

First Author: Michael Dickinson

First Author: Christopher Flowers